We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Brain Stent Eases Pseudotumor Symptoms

By HospiMedica International staff writers
Posted on 01 Apr 2013
A new study shows that an endovascular stent placed in the transverse sinus (TS) significantly reduces the pressure gradient of pseudotumor cerebri (PTC), improving tinnitus as well as visual function.

Researchers at the Uniformed Services University of the Health Sciences (USUHSj Bethesda, MD, USA) and Johns Hopkins University (Baltimore, MD, USA) conducted a study involving 12 patients with PTC. More...
All patients had initial neurological, neuro-ophthalmological, and imaging assessments; regardless of the findings, all were treated with medical therapy. If medical therapy failed and TS stenosis was detected on contrast-enhanced magnetic resonance imaging (MRI) or computerized tomography (CT) venography, catheter cerebral angiography with venous manometry was performed. If a mean pressure gradient of 4 mmHg or greater was present, unilateral TS stenting was performed.

The results showed that TS stenting significantly decreased the PTC pressure gradient in all cases, and that unilateral stenting was sufficient to reduce pressure gradients, even when the stenosis was bilateral. At a mean follow-up of 16 months, tinnitus had improved in all patients, and 10 of 12 patients had improvement in visual function. Seven of the patients also had significant improvement in headaches. The study was published on March 14, 2013, in the Journal of Neuro-Ophthalmology.

“Following stenting, headaches resolved completely in two patients and improved in five, but persisted in the remaining five patients,” concluded lead author Martin Radvany, MD, of USHUS, and colleagues. “Of five patients in this series who continued to have headaches despite normalization of CSF pressure after stenting, four responded to migraine prophylactic medications.”

Pseudotumor cerebri presents as raised intracranial pressure (ICP) with normal cerebrospinal fluid (CSF) analysis, and without clinical or imaging evidence of a space-occupying pathology. Around 10%–20% of patients will experience vision loss caused by prolonged papilledema, with secondary optic nerve atrophy. Conventional treatment consists of oral acetazolamide, which is limited in long-term use by its side effects. Surgical options include optic nerve sheath fenestration and CSF diversion procedures.

Related Links:

Uniformed Services University of the Health Sciences
Johns Hopkins University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Wound Irrigation Solution
Prontosan®
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.